Public Health
Scientists Fault 'Off Label' Pharma Marketing
|
A major drug distributor used “deception and misinformation” to promote the unapproved, “off label” use of an epilepsy drug, two researchers from the University of California-San Francisco claim. What’s more, they claim the practice is widespread in the pharmaceutical industry, while other sources say the side effects of off-label prescriptions can be deadly. Writing in the New England Journal of Medicine, the UCSF researchers say their review of a 1995 lawsuit against Parke-Davis revealed a “systematic” marketing campaign by the company to promote Neurontin, approved by the Food and Drug Administration to treat epilepsy, for unapproved conditions such as pain, migraines and bipolar disorder. The company, now owned by Pfizer, pleaded guilty in 2004, and paid over $430 million in fines for trying to suppress publication of unfavorable peer-reviewed research, allowing sales reps to pitch “off label” uses to doctors, and providing gifts and financial compensation to doctors to attend presentations about Neurontin. The researchers say the extensive marketing and influence campaign was “disguised” as educational programming for researchers, and amounted to a manipulation of the medical establishment that pushed Neurontin sales from $93 million to $3 billion in a decade.